|
EP0693084A4
(en)
*
|
1993-04-06 |
1999-06-02 |
Hutchinson Fred Cancer Res |
CHIMERAL CYTOKINE RECEPTORS IN LYMPHOCYTE
|
|
US5855887A
(en)
|
1995-07-25 |
1999-01-05 |
The Regents Of The University Of California |
Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US6051227A
(en)
|
1995-07-25 |
2000-04-18 |
The Regents Of The University Of California, Office Of Technology Transfer |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
DE69834257T2
(de)
|
1997-04-30 |
2007-01-04 |
Klingemann, Hans |
Natürliche killerzelllinien und verfahren zu ihrer verwendung
|
|
US8034332B2
(en)
|
1997-04-30 |
2011-10-11 |
Conkwest, Inc. |
Interleukin-secreting natural killer cell lines and methods of use
|
|
US6645490B2
(en)
*
|
1998-03-02 |
2003-11-11 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
|
|
DZ2788A1
(fr)
*
|
1998-05-15 |
2003-12-01 |
Bayer Ag |
Agonistes et antagonistes selectifs à IL-2.
|
|
EE05627B1
(et)
|
1998-12-23 |
2013-02-15 |
Pfizer Inc. |
CTLA-4 vastased inimese monoklonaalsed antikehad
|
|
NZ517202A
(en)
|
1999-08-24 |
2004-05-28 |
Medarex Inc |
Human CTLA-4 antibodies and their uses
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
EP1221973B1
(en)
|
1999-10-04 |
2007-05-30 |
Novartis Vaccines and Diagnostics, Inc. |
CD40 antagonist for treating psoriasis
|
|
US20030059427A1
(en)
|
2000-04-28 |
2003-03-27 |
Force Walker R. |
Isolation and characterization of highly active anti-CD40 antibody
|
|
CA2658221C
(en)
|
2001-04-27 |
2012-11-27 |
Kyowa Kirin Co., Ltd. |
Anti-cd40 monoclonal antibody
|
|
AU2002257420A1
(en)
|
2001-05-01 |
2002-11-11 |
National Research Council Of Canada |
A system for inducible expression in eukaryotic cells
|
|
EP2206517B1
(en)
|
2002-07-03 |
2023-08-02 |
Ono Pharmaceutical Co., Ltd. |
Immunopotentiating compositions comprising anti-PD-L1 antibodies
|
|
US7276478B2
(en)
*
|
2003-09-25 |
2007-10-02 |
Zymogenetics, Inc. |
Methods of treating autoimmune diseases using IL-21
|
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
|
CN100379762C
(zh)
|
2003-12-08 |
2008-04-09 |
中国人民解放军军事医学科学院生物工程研究所 |
人血清白蛋白与白细胞介素2的融合蛋白及其编码基因
|
|
ES2397631T3
(es)
|
2003-12-25 |
2013-03-08 |
Kyowa Hakko Kirin Co., Ltd. |
Mutante antagonista de anticuerpos ANTI-CD40
|
|
US7674621B2
(en)
|
2004-05-21 |
2010-03-09 |
The United States Of America As Represented By The Department Of Health And Human Services |
Plasmids and phages for homologous recombination and methods of use
|
|
EP2801583B1
(en)
*
|
2004-07-10 |
2018-04-25 |
Fox Chase Cancer Center |
Genetically modified human natural killer cell lines
|
|
US20080280781A1
(en)
|
2005-01-16 |
2008-11-13 |
Georgia Tech Research Corporation |
Methods and Compositions for Increasing Membrane Permeability
|
|
ES2720160T3
(es)
|
2005-05-09 |
2019-07-18 |
Ono Pharmaceutical Co |
Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
|
|
US8945564B2
(en)
|
2006-04-21 |
2015-02-03 |
Novartis Ag |
Antagonist anti-CD40 antibody pharmaceutical compositions
|
|
EP2049547A2
(en)
|
2006-07-21 |
2009-04-22 |
Gilead Sciences, Inc. |
Aza-peptide protease inhibitors
|
|
US20090025274A1
(en)
|
2007-07-23 |
2009-01-29 |
Tim Lail |
Animal trap
|
|
GB0815216D0
(en)
*
|
2008-08-21 |
2008-09-24 |
Asterion Ltd |
Interleukin
|
|
BRPI0919377A2
(pt)
|
2008-09-26 |
2016-09-27 |
Dana Farber Cancer Inst Inc |
anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
|
|
PT3178851T
(pt)
|
2010-03-31 |
2020-07-17 |
Boehringer Ingelheim Int |
Anticorpos anti-cd40
|
|
US8734774B2
(en)
*
|
2010-04-02 |
2014-05-27 |
University Of Rochester |
Protease activated cytokines
|
|
ES2682078T3
(es)
|
2010-06-11 |
2018-09-18 |
Kyowa Hakko Kirin Co., Ltd. |
Anticuerpo anti-TIM-3
|
|
WO2012111762A1
(ja)
|
2011-02-17 |
2012-08-23 |
協和発酵キリン株式会社 |
抗ｃｄ４０抗体の高濃度製剤
|
|
WO2012149356A2
(en)
|
2011-04-29 |
2012-11-01 |
Apexigen, Inc. |
Anti-cd40 antibodies and methods of use
|
|
WO2013006490A2
(en)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
|
KR101981873B1
(ko)
|
2011-11-28 |
2019-05-23 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
WO2013177187A2
(en)
*
|
2012-05-22 |
2013-11-28 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
|
|
CN104918957B
(zh)
|
2012-10-30 |
2018-11-16 |
埃派斯进有限公司 |
抗-cd40抗体及其使用方法
|
|
NZ711807A
(en)
*
|
2013-02-06 |
2020-06-26 |
Celgene Corp |
Modified t lymphocytes having improved specificity
|
|
HK1216231A1
(zh)
|
2013-06-03 |
2016-10-28 |
Novartis Ag |
Anti-pd-l1抗体及mek抑制剂及/或braf抑制剂的混合物
|
|
EP3157958B1
(en)
|
2014-06-18 |
2020-05-06 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Car-expressing nk-92 cells as cell therapeutic agents
|
|
BR112017000497B1
(pt)
|
2014-07-11 |
2023-12-26 |
Ventana Medical Systems, Inc |
Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
|
|
MA40094B1
(fr)
*
|
2014-08-06 |
2022-05-31 |
Univ Miami |
Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
UY36351A
(es)
|
2014-10-14 |
2016-06-01 |
Novartis Ag |
Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
|
|
PL3215532T3
(pl)
|
2014-11-06 |
2020-03-31 |
F. Hoffmann-La Roche Ag |
Przeciwciała anty-TIM3 i sposoby ich zastosowania
|
|
ES2857998T3
(es)
*
|
2015-02-12 |
2021-09-29 |
Univ Health Network |
Receptores de antígenos quiméricos
|
|
JP2018510151A
(ja)
|
2015-03-06 |
2018-04-12 |
ソレント・セラピューティクス・インコーポレイテッド |
Ｔｉｍ３に結合する抗体医薬
|
|
CN113604435A
(zh)
|
2015-03-27 |
2021-11-05 |
南克维斯特公司 |
用于治疗癌症的被遗传修饰的nk-92细胞和单克隆抗体
|
|
CA2982984C
(en)
|
2015-04-20 |
2023-10-17 |
Effector Therapeutics, Inc. |
Inhibitors of immune checkpoint modulators for use in treating cancer and infections
|
|
CA2993177A1
(en)
|
2015-07-22 |
2017-01-26 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind lag3
|
|
US20180230431A1
(en)
|
2015-08-07 |
2018-08-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Therapy
|
|
AR105654A1
(es)
|
2015-08-24 |
2017-10-25 |
Lilly Co Eli |
Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
|
|
LU92821B1
(en)
|
2015-09-09 |
2017-03-20 |
Mologen Ag |
Combination comprising immunostimulatory oligonucleotides
|
|
SMT202100506T1
(it)
|
2015-10-02 |
2021-11-12 |
Hoffmann La Roche |
Anticorpi bispecifici specifici per pd1 e tim3
|
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗ｌａｇ３抗體及其用途
|
|
CA3021455A1
(en)
*
|
2016-04-20 |
2017-10-26 |
Fred Hutchinson Cancer Research Center |
Immunomodulatory il2r fusion proteins and uses thereof
|
|
EP3848393A1
(en)
|
2016-05-18 |
2021-07-14 |
Boehringer Ingelheim International GmbH |
Antibody molecules for cancer treatment
|
|
JP7027401B2
(ja)
|
2016-07-14 |
2022-03-01 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｔｉｍ３に対する抗体およびその使用
|
|
MX2019010206A
(es)
|
2017-02-28 |
2019-12-11 |
Seattle Genetics Inc |
Anticuerpos anti inmunorreceptor de linfocitos t con dominios de motivo de inactivación basado en tirosina de inmunorreceptor e inmunoglobulina (tigit).
|
|
PL3606955T3
(pl)
|
2017-04-05 |
2025-02-24 |
F. Hoffmann-La Roche Ag |
Przeciwciała dwuswoiste swoiście wiążące się z PD1 i LAG3
|
|
EP3679145A2
(en)
|
2017-09-08 |
2020-07-15 |
Poseida Therapeutics, Inc. |
Compositions and methods for chimeric ligand receptor (clr)-mediated conditional gene expression
|
|
TW202023625A
(zh)
|
2018-08-23 |
2020-07-01 |
美商西雅圖遺傳學公司 |
抗tigit抗體
|
|
US20240207405A1
(en)
|
2021-04-28 |
2024-06-27 |
The General Hospital Corporation |
Il2 tethered to its receptor il2rbeta and pore-forming proteins as a platform to enhance immune cell activity
|